NL-OMON46799CompletedNot Applicable
Development of a dermal TLR4 challenge in healthy volunteers. - Skin inflammation challenge with TLR4 agonist
Conditions
Trial Snapshot
- Phase
- Not Applicable
- Status
- Completed
- Enrollment
- 18
Study Overview
Brief Summary
No summary available.
Study Design
- Study Type
- Interventional
Eligibility Criteria
- Ages
- 18 to 99 (—)
Inclusion Criteria
- •1. Healthy male subjects, 18 to 45 years of age, inclusive. Healthy status is defined by absence of evidence of any active or chronic disease following a detailed medical and surgical history, a complete physical examination including vital signs, 12-lead ECG, hematology, blood chemistry, blood serology and urinalysis;
- •2. Body mass index (BMI) between 18 and 30 kg/m2, inclusive, and with a minimum weight of 50 kg;
- •3. Fitzpatrick skin type I-III (Caucasian);
- •4. Able and willing to give written informed consent and to comply with the study restrictions.
Exclusion Criteria
- •Eligible subjects must meet none of the following exclusion criteria at screening:
- •1. Any disease associated with immune system impairment, including auto-immune diseases, HIV and transplantation patients;
- •2. Any vaccination within the last 3 months;
- •3. Family history of psoriasis;
- •4. History of pathological scar formation (keloid, hypertrophic scar);
- •5. Have any current and / or recurrent pathologically, clinical significant skin condition at the treatment area (i.e. atopic dermatitis);
- •6. Hypersensitivity for dermatological marker at screening;
- •7. Requirement of immunosuppressive or immunomodulatory medication within 30 days prior to enrollment or planned to use during the course of the study;
- •8. Excessive sun exposure or a tanning booth within 3 weeks of enrollment;
- •9. Participation in an investigational drug or device study within 3 months prior to screening or more than 4 times a year;
- •10. Loss or donation of blood over 500 mL within three months prior to screening. Or the donation of plasma within 14 days prior to screening;
- •11. Current smoker and/or regular user of other nicotine-containing products (e.g., patches);
- •12. History of or current drug or substance abuse considered significant by the PI (or medically qualified designee), including a positive urine drug screen.
Investigators
Similar Trials
Completed
Not Applicable
Development of skin inflammation model in healthy volunteersThe aim of this study is to characterize the inflammatory response upon intradermal LPS injection in healthy volunteersISRCTN45261648Centre for Human Drug Research18
Completed
Not Applicable
TLR4 Polymorphisms and Risk of Skin CancerSkin CancerNCT03122366University of Alabama at Birmingham392
Not yet recruiting
Not Applicable
CCR4 expression in rare subtypes of cutaneous T-cell lymphomas (CTCL)a non-interventional restrospective multicenter studyORPHA:178528ORPHA:86884ORPHA:178522ORPHA:178533ORPHA:86885C84.5C84.0C86.3C84.8Other mature T/NK-cell lymphomasMycosis fungoidesSubcutaneous panniculitis-like T-cell lymphomaCutaneous T-cell lymphoma, unspecifiedDRKS00034511Charité-Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Department of Dermatology, Venereology and Allergology, Berlin, Germany50
Withdrawn
Phase 1
Safety and Efficacy of Abatacept for Treating Chronic Cytopenia in Cytotoxic T-Lymphocyte Antigen 4 (CTLA4) HaploinsufficiencyCTLA4 HaploinsufficencyChronic CytopeniaNCT03733067National Institute of Allergy and Infectious Diseases (NIAID)
Completed
Not Applicable
B cell phenotyping in malaria patientsCTRI/2018/02/012087Tata Institute of Fundamental Research83